TrialSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).

Bernardo Rapoport et al.PubMed ↗Publisher ↗

No numbers read from the abstract.